Business Context and Reporting Period
This Form 8-K was filed by Fluidigm Corporation on December 12, 2018, reporting events occurring on December 11, 2018. The filing details a public offering of common stock. Note: The metadata provided lists "STANDARD BIOTOOLS INC.", but the filing text explicitly identifies the registrant as "FLUIDIGM CORPORATION".
Key Financial Metrics
- Shares Offered: 8,150,000 shares of common stock.
- Public Offering Price: $6.75 per share.
- Price to Underwriters: $6.345 per share.
- Expected Net Proceeds: Approximately $51.3 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 1,222,500 additional shares.
- Maximum Potential Proceeds: Approximately $59.1 million if the over-allotment option is exercised in full.
Material Changes
The primary material change is the execution of a purchase agreement for a new equity offering. This transaction represents a significant capital raise intended to increase the company's liquidity. The filing does not provide comparative financial data (revenue, profit, or margins) for prior periods as this is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use net proceeds for general corporate purposes, including:
- Working capital.
- Capital expenditures.
- Continued research and development for products and technologies.
- Funding possible investments in or acquisitions of complementary businesses, products, or technologies.
Lock-Up Agreements: Executive officers and directors have entered into lock-up agreements prohibiting the sale or transfer of securities for a 75-day period, subject to certain exceptions.
Closing Date: Expected on or about December 14, 2018, subject to customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected December 14, 2018).
- Confirm whether the underwriters exercise the 30-day option to purchase the additional 1,222,500 shares.
- Review the full text of the Purchase Agreement (Exhibit 1.1) for specific representations and warranties.
- Monitor the company's subsequent filings for the actual allocation of proceeds and any announced acquisitions.